No Data
Those Who Invested in China Resources Pharmaceutical Group (HKG:3320) Three Years Ago Are up 72%
The new policy of prepayment of medical insurance fund has been released, and the pharmaceutical sector has ushered in a sharp rise. Experts believe it may be a way for medical institutions to release funding pressure.
On the 11th, the "Notice on Prepayment of Medical Insurance Fund" was issued, requiring the unified and improved basic medical insurance fund prepayment system at the national level. Experts believe that the prepayment system can effectively alleviate the problem of pharmaceutical industry debt, accelerate the turnover of funds for pharmaceutical companies. The medical sector showed a significant upward trend today, with listed companies attributing the rise to investor sentiment.
Everbright Securities: Empowering commercial health insurance to promote payment diversification, medical insurance prepayment alleviates funding pressure.
After the implementation of the medical insurance prepayment system, it is expected to effectively alleviate the financial pressure of medical institutions in the corresponding areas, thereby improving the enterprise account payment status of pharmaceutical procurement and consumables channels, conducive to the overall development of the cash flow chain of medical institutions-pharmaceutical distribution-pharmaceutical manufacturing.
Multiple bullish factors boost pharmaceutical Hong Kong stocks. Institutions say they still face this risk in the short term.
①What are the policy measures to support the field of innovative drugs? ②What unfavorable effects on domestic pharmaceutical stocks might Trump's election bring about?
Announcement Highlights | china overseas: Sales in October increased by 66% year-on-year; alibaba continues to repurchase approximately 19.9886 million US dollars of shares.
Concord Ne (00182.HK): The total power generation in the first 10 months was 7166.91GWh, a year-on-year increase of 12.79%; Poly Property: Sales revenue in October was 8.6 billion yuan.
chinare pharma (03320.HK) completes acquisition of 100% equity of Green Cross HK
Gelonghui, November 6th | Chinares Pharma (03320.HK) announced that the board of directors happily announced that the share transfer registration with the relevant counterpart department of the State Administration for Market Regulation has been completed. Therefore, as of the date of this announcement, the acquisition of 100% equity of Green Cross HK is recommended to have been completed in accordance with the terms and conditions of the share purchase agreement. After completion, Green Cross HK becomes a wholly-owned subsidiary of China Resources Boya Bio-Pharmaceutical Group and is accounted for as a non-wholly-owned subsidiary of the Company.
No Data
No Data
